newsfilter
← Latest News
Business Wire·

Nordson Corporation Reports Record Fourth Quarter and Fiscal Year 2025 Results

NDSN
  • Nordson Corporation reported Q4 2025 sales of $752 million, a 1% increase year-over-year, driven by 2% favorable currency translation & 1% acquisition impact, partially offset by medical contract manufacturing divestiture & 1% organic sales decrease.
  • Q4 2025 adjusted earnings per diluted share were $3.03, representing a 9% increase from the prior year, while GAAP earnings per share were $2.69.
  • Full-year 2025 sales reached a record $2.8 billion, a 4% increase over the prior year, driven by 6% acquisition impact offset by 3% organic volume decrease.
  • Full-year 2025 adjusted earnings per diluted share were $10.24, a 5% increase year-over-year, with GAAP earnings per share at $8.51.
  • Q4 2025 EBITDA was $256 million (34% of sales), a 6% increase from the prior year, with free cash flow conversion at 128%.
  • Full-year 2025 EBITDA was $900 million (32% of sales), achieving the company's strategy goal, with record full-year free cash flow of $661 million (136% conversion rate).
  • Industrial Precision Solutions segment sales decreased 2% to $362 million due to 4% organic decline in polymer processing systems.
  • Medical & Fluid Solutions segment sales increased 10% to $220 million, driven by 7% organic growth & 2% acquisition impact from Atrion.
  • Advanced Technology Solutions segment sales decreased 4% to $171 million due to a 5% organic decline in test & inspection systems.
  • Fiscal 2026 sales are forecasted between $2,830 million & $2,950 million, with adjusted earnings per share forecasted between $10.80 & $11.50.
  • Fiscal 2026 Q1 sales guidance is $630 million to $670 million, with adjusted earnings per share guidance of $2.25 to $2.45.
  • The company entered fiscal 2026 with a backlog of approximately $600 million, up 5% from the prior year end, excluding divested business.
  • Nordson maintained gross margins of 55% in 2025 while continuing capital allocation toward share repurchases, dividends, & debt reduction.
  • The medical contract manufacturing business divestiture closed on September 2, 2025, contributing to the organic sales decrease.